Strong antifungal activity of SS750, a new triazole derivative, is based on its selective binding affinity to cytochrome P450 of fungi

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 2, 2002, Pages 308-314

  Matsumoto, Masaru ^a   Ishida, Kazuya ^a   Konagai, Akihiro ^a   Maebashi, Kazunori ^a   Asaoka, Takemitsu ^a  

^a SSP CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DIFLUOROPHENYL) 1 (ETHYLSULFONYL) 1,1 DIFLUORO 3 (1H 1,2,4 TRIAZOL 1 YL) 2 PROPANOL; CYCLOPHOSPHAMIDE; CYTOCHROME P450; FLUCONAZOLE; ITRACONAZOLE; SS 750; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; BINDING AFFINITY; CANDIDA; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDIASIS; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DOSE RESPONSE; DRUG BINDING; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIFUNGAL AGENTS; BINDING SITES; CANDIDA ALBICANS; CANDIDIASIS; CELL-FREE SYSTEM; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE MODELS, ANIMAL; ERGOSTEROL; IMMUNOCOMPROMISED HOST; LUNG DISEASES; MALE; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; MICROSOMES;

EID: 0036148303     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.2.308-314.2002     Document Type: Article

References (24)

1. The mode of antifungal action of tolnaftate
2. New antifungal 1,2,4-triazoles with difluoro (substituted sulfonyl) methyl moiety
3. Epidemiology of nosocomical fungal infections
4. Overview of medically important antifungal azole derivatives
5. Cytochrome P-450-dependent 14α-demethylation of lanosterol in Candida albicans
6. Antifungal agents in the 1990s
7. Infection in the bone marrow transplant recipient and role of the microbiology laboratory in clinical transplantation
8. Antifungal prophylaxis during neutropenia and immunodeficiency
9. Protein measurement with the Folin phenol reagent
10. Origin of differences in susceptibility of Candida krusei to azole antifungal agents
11. Inhibition of sterol biosynthesis in Candida albicans by imidazole-containing antifungals
12. Effect of carrier solvents on the efficacy of oral itraconazole therapy in aspergillosis in mice
13. The carbon monoxide-binding pigment of liver microsomes
14. Mechanism of fluconazole resistance in Candida krusei
15. Infections in solid-organ transplant recipients
16. Adverse drug reactions to systemic antifungals: Prevention and management
17. Marked intra-and inter-patient variability of itraconazole steady state plasma concentrations
18. Resistance of Candida species to fluconazole
19. Amphotericin B nephrotoxicity
20. Interaction of azole derivatives with cytochrome P-450 isozymes in yeast, fungi, plants and mammalian cells
21. Comparison of D0870, a new triazole antifungal agent, to fluconazole for inhibition of Candida albicans cytochrome P-450 by using in vitro assays
22. Fungemia in children infected with the human immunodeficiency virus: New epidemiologic patterns, emerging pathogens, and improved outcome with antifungal therapy